Key words: Vasculitis, treatment, cyclophosphamide, rituximab, ANCA
نویسنده
چکیده
Medizinische Klinik, Kreiskliniken Esslingen, Plochingen, Germany. Please address correspondence and reprint requests to: Prof. Dr. med. Bernhard Hellmich, Kreiskliniken Esslingen, Klinik Plochingen, Medizinische Klinik, Am Aussichtsturm 5, 73207 Plochingen, Germany. E-mail: [email protected] Received on January 21, 2010; accepted on February 1, 2010. Clin Exp Rheumatol 2010: 28 (Suppl. 57): S98-S103. © Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2010.
منابع مشابه
Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide f...
متن کاملKey words: vasculitis, ANCA, granulomatosis with polyangiitis, microscopic polyangiitis, Birmingham Vasculitis Activity Score, Vasculitis Damage Index, cyclophosphamide, rituximab
NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom. Raashid Luqmani, DM, FRCP, Professor Please address correspondence to: Prof. Raashid Luqmani, NIHR Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, Unive...
متن کاملModerator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?
Experience with rituximab in patients with new ANCA-associated vasculitis (AAV) is still very limited, especially in patients with severe (organ- or life-threatening) AAV. Rituximab may be more effective in anti-PR3 AAV, but potentially less effective in some granulomatous manifestations of AAV. We do not know what the response is to rituximab on the tissue level. Rituximab induction needs to b...
متن کاملRituximab versus cyclophosphamide for ANCA-associated vasculitis.
BACKGROUND Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based regimen. METHODS We conducted a multicenter, randomized, double-blind, double-dummy, noninferior...
متن کاملManagement of ANCA-associated vasculitis: Current trends and future prospects
The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides are a spectrum of heterogeneous autoimmune diseases characterized by necrotizing small vessel vasculitis and the presence of ANCA. These chronic multisystem disorders may be life-threatening if there is major organ involvement, such as acute renal failure or pulmonary hemorrhage, and require significant initial immunosuppressi...
متن کامل